{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Post-transplant+Ruxolitinib", "query": { "intervention": "Post-transplant Ruxolitinib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Post-transplant+Ruxolitinib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T11:26:54.958Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04055844", "title": "Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myeloid and Monocytic Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Donor Lymphocyte Infusion (DLI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 14, "start_date": "2020-02-17", "completion_date": "2022-09-06", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • St Louis, Missouri • Rochester, New York", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04055844" }, { "nct_id": "NCT03616184", "title": "Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft-versus-host-disease (GVHD)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-09-05", "completion_date": "2023-06-12", "has_results": true, "last_update_posted_date": "2023-10-05", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 5, "location_summary": "Tampa, Florida • Omaha, Nebraska • Cleveland, Ohio + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03616184" }, { "nct_id": "NCT05579769", "title": "Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancy", "Myeloid Malignancy" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Anti-thymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Total Body Irradiation (radiation treatment)", "type": "RADIATION" }, { "name": "Bone marrow infusion", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 3, "start_date": "2023-03-14", "completion_date": "2024-05-08", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579769" }, { "nct_id": "NCT04807777", "title": "Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-04-07", "completion_date": "2023-10-04", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04807777" }, { "nct_id": "NCT03674047", "title": "Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Other Cancer" ], "interventions": [ { "name": "ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 50, "start_date": "2019-04-19", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 7, "location_summary": "Duarte, California • Tampa, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03674047" }, { "nct_id": "NCT03922724", "title": "Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphomas", "Lymphoproliferative Disorders", "Immune System Diseases" ], "interventions": [ { "name": "ATL-RIC", "type": "DRUG" }, { "name": "mRIC", "type": "DRUG" }, { "name": "allo HCT", "type": "PROCEDURE" }, { "name": "RIC", "type": "DRUG" }, { "name": "GVHD prophylaxis", "type": "DRUG" }, { "name": "IOC", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 91, "start_date": "2019-04-18", "completion_date": "2030-10-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03922724" }, { "nct_id": "NCT03112603", "title": "A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft-versus-host Disease (GVHD)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Extracorporeal photopheresis (ECP)", "type": "DRUG" }, { "name": "Low-dose methotrexate (MTX)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 330, "start_date": "2017-06-29", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 38, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03112603" }, { "nct_id": "NCT04908735", "title": "Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic Stem Cell Transplant (HSCT)", "Bronchiolitis Obliterans (BO)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "5 Years to 60 Years" }, "enrollment_count": 7, "start_date": "2021-11-12", "completion_date": "2025-11-16", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Cincinnati, Ohio", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04908735" }, { "nct_id": "NCT02528877", "title": "Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia in Remission", "Primary Myelofibrosis", "Primary Myelofibrosis, Prefibrotic Stage", "Secondary Acute Myeloid Leukemia", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2015-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-09-14", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02528877" }, { "nct_id": "NCT07356245", "title": "Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Lymphoma", "Graft Versus Host Disease", "Lymphoma, T-Cell", "Peripheral T Cell Lymphoma", "T-cell Prolymphocytic Leukemia", "Cutaneous T Cell Lymphoma", "Adult T-cell Leukemia/Lymphoma", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Positron emission tomography-computed tomography", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Jonathan Brammer", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2026-02-12", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-28T11:26:54.958Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07356245" } ] }